What oral and intrathecal antispasmodic (muscle relaxant) options and dosing regimens are recommended for managing spasticity in patients with spinal cord compression?

Antispasmodics for Spinal Cord Compression

For spasticity from spinal cord compression, start with oral tizanidine, dantrolene, or baclofen, and escalate to intrathecal baclofen for severe, refractory cases—avoid benzodiazepines entirely.

Oral Antispasmodic Options

The FDA-approved oral medications for spasticity management include tizanidine, baclofen, and dantrolene 1. While the available guidelines address stroke rather than spinal cord compression specifically, the pharmacologic principles apply to spinal cord-related spasticity.

First-Line Oral Agents

Tizanidine is particularly effective for chronic spasticity with demonstrated improvement in both spasticity and pain without loss of motor strength 1. This makes it advantageous when preserving residual motor function is critical.

Oral baclofen has established efficacy but carries significant sedation risk and may have less impact on spasticity compared to other conditions 1. The sedation can be dose-limiting, particularly at doses >60 mg/day 2.

Dantrolene offers the benefit of minimal cognitive side effects 1. However, evidence supporting its use is limited, and it showed no benefit when started prophylactically before disabling spasticity develops 1.

Critical Contraindication

Diazepam and all benzodiazepines are contraindicated due to deleterious effects on neurological recovery and excessive sedation 1. This recommendation is explicit and strong across guidelines.

Dosing Considerations

Oral baclofen adverse effects are dose-related and typically appear at doses >60 mg/day 2. Between 25-75% of patients experience adverse effects including muscle weakness, nausea, somnolence, and paresthesia 3, 2. Approximately 25-30% of patients fail to respond to oral baclofen or cannot tolerate it 3.

Intrathecal Baclofen Therapy

Indications

Intrathecal baclofen (ITB) should be considered when:

• Spasticity results in pain, poor skin hygiene, or decreased function
• Oral medications fail to control symptoms
• Intolerable side effects occur with oral agents 1

ITB can be initiated as early as 3-6 months after injury for patients refractory to other treatments 4.

Dosing Protocol

Test dose: Start with 50 μg intrathecal baclofen; 42% of patients respond to this dose, while 34% require >100 μg 5.

Initial therapy: After pump implantation, the mean daily dose increase is approximately 180 μg from baseline 5.

Maintenance dose: The effective average dose is 360 μg per day 5. After 1 year, patients typically require a median dose of 168 mg/24 hours (range 30-725 mg) 6.

Long-term adjustments: Spinal cord injury patients require only modest dose increases over time (mean 113-121% increase over 7-10 years), unlike progressive conditions like multiple sclerosis which require 157-194% increases 6. This suggests that substantial dose escalation in SCI patients should prompt evaluation for pump failure, triggering factors, or progressive spinal disease 6.

Safety Profile

ITB delivers baclofen directly to cerebrospinal fluid at concentrations less than one-hundredth of oral doses, minimizing central side effects like drowsiness and confusion 3. Complications occur in 25% of cases, including infection, skin perforation, catheter occlusion, and pump malfunction 5. However, 85% of patients with complications can continue intrathecal therapy after revision 5.

Advantages Over Oral Route

• Bypasses blood-brain barrier, concentrating drug at site of action
• Programmable continuous infusion allows dose titration throughout the day
• Can provide lower tone for ambulation during daytime and increased dosing at night for sleep
• Reversible intervention compared to neurosurgical options 3

Adjunctive Treatments

Botulinum toxin injections are recommended for localized spasticity affecting specific muscle groups, particularly when spasticity interferes with hygiene, dressing, or limb positioning 1, 4. However, evidence specific to spinal cord injury is limited 7.

Physical modalities such as neuromuscular electrical stimulation or vibration may temporarily improve spasticity as adjuncts to rehabilitation 4.

Treatment Algorithm

1. Initial management: Start with positioning, passive stretching, and range of motion exercises several times daily 1
2. Pharmacologic escalation: Trial oral tizanidine, dantrolene, or baclofen based on patient-specific factors (sedation tolerance, cognitive status, motor preservation needs)
3. Refractory cases: Consider intrathecal baclofen if oral agents fail or cause intolerable side effects, particularly when spasticity causes pain, hygiene problems, or functional limitations
4. Targeted intervention: Add botulinum toxin for focal spasticity affecting specific functional goals
5. Last resort: Neurosurgical procedures (selective dorsal rhizotomy, dorsal root entry zone lesions) carry significant operative risks and lack clinical trial evidence 1

Critical Pitfalls

• Never use benzodiazepines for spasticity management in neurological injury
• When changing ITB solution concentrations, always calculate and program a bridge bolus to compensate for residual baclofen in the pump and catheter—dosage errors are a significant source of morbidity 8
• Large dose escalations in ITB for SCI patients should trigger investigation for mechanical problems or disease progression, not automatic dose increases 6
• Oral baclofen discontinuation rates due to adverse effects range from 4-27% 3